Characterization of Celecoxib β-Cyclodextrin Inclusion Complexes Using Solvent Evaporation Method
Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) used for the treatment of pain and inflammation. Celecoxib is included in class II in the Biopharmaceutis ClassificationAsystem drug (BCS) which has low solubility and high permeability. This study aims to increase the solubility and dissolution rate of celecoxib by characterizing the inclusion complex of celecoxib β-cyclodextrin. Inclusion complexes were prepared by the solvent evaporation method using a water-soluble polymer, β-cyclodextrin. The inclusion complexes were prepared in a 1: 1 ratio between celecoxib and β-cyclodextrins. As a comparison, a physical mixture with the same composition was made. Powder mixtures of physics and inclusion complexes characterized by physicochemical properties include: FT-IR spectroscopy analysis, DSC analysis, assay and dissolution test. The dissolution test was determined by the paddle method. The results of characterization of the inclusion complex using FT-IR spectrophotometry showed a shift in the wave number as well as the physical interaction between celecoxib and β-cyclodextrin. The results of the DSC (Differential Scanning Calorimetry) decreased the enthalpy and melting point between celecoxib, the physical mixture and the inclusion complex. The dissolution test showed an increase in dissolution rate at 60 minutes, namely Celecoxib 55.03%, physical mixture 61.58% and inclusion complex 67.53%.
2. Reintjes, T. (2011). Solubility enhancement with BASF pharma polymers solubilizer compendium. Germany: Pharma ingredients & services.
3. J. Fort. Celecoxib, a COX-2-specific inhibitor: the clinical data. Am J.Orthop,1999;(28):13–18.
4. Loftsson, T., & Brewster, M. E.Pharmaceutical applications of β-siklodekstrin, drug solubilization and stabilization. J Pharm Sci. 1996; 85(10):1017-1024.
5. Loftsson T, Jarho P, Masson M, Jarvinen T. Cylodextrin in Drug Delivery, Expert Opinion Drug Delivey, 2005; 2:335-351
6. Duchene, D. (2011). Cyclodextrin And Their Inclusion Complexes, In Bilensoy, E. Cyclodextrin In Pharmaceutics, Cosmetics and Biomedicine. John Wiley & Sons, Inc., New Jersey, Canada.
7. Patil, J. S., Kadam, D. V., Marapur, S. C., & Kamalapur, M. V. Inclusion Complex System ; A novel technique to improve the solubility and bioavailability of poorly soluble drugs. International Journal of Pharmaceutical Sciences Review and Reserch, 2010; 2, (2), 29-34.
8. Sahoo, S., Chakraborti, K,C., Misrha,C, S., Nanda, Nath., Upendra & Naik, S. FTIR and XRD Investigations Of Some Flouroquinolones. International Journal Of Pharmacy and Pharmacetical Sciences.2011; 3(3).
9. Liu, Y., Sun, C., Hao, Y., Jiang, T., Zheng., & Wang,S. Mechanism of dissolution enhancement and bioavaibility of poorly water soluble celecoxib by preparing stable amorphous nanoparticles. Journal of pharmacy & pharmaceutical sciences,2008; 13(4):589.
10. Reddy, M.N., M., Rehana, T., Ramakrishna, S., Chowdary, K. P.R., &Diwan,P.V.β-cyclodextrin complexes of celecoxib: molecular-modeling, characterization, and dissolution studies. AAPS PharmSci,2004; 6(1).
11. Jouyban-Gharamaleki, V., Soleymani, J., Jouyban-Gharamaleki, K., Suleymanov, T. A., & Jouyban, A. Solubilization of celecoxib, lamotrigine and phenytoin using ethanol and a nonionic surfactant. Journal of Molecular Liquids, 2017; 243:715–719.
12. Dachriyanus. (2004). Analisis struktur sensyawa organik secara spektroskopi. Padang: Andalas Universitty Press.
13. Ginting, A., Sutri, I., & Jan, S. Penentuan Parameter Uji dan Ketidakpastian Pengukuran Kapasitas Panas Pada Differentian Scanning Calorimeter. J. Tek. Bhn. Nukl.2005; 1(1):1-57.
14. European Pharmacopoeia Commission. (2014) . European Directorate for the Quality of Medicines &Healthcare European Pharmacopoeia 8th Edition, Strasbourg : Council Of Europe .
15. Kementerian Kesehatan Republik Indonesia. (2014). Farmakope Indonesia. (Edisi V). Jakarta: Kementrian Kesehatan Republik Indonesia.
16. Rowe, R. C., Sheskey, P. J., & Quinn, M. E. (2009). Handbook of pharmaceutical exipients (6th ed). London: Pharmaceutical Press.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).